Evaluation of the Pharmacokinetic Properties and the Tolerance of Raltegravir During the Third Trimester of Pregnancy
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
Price : $35 *
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Acronyms RalFE
- 18 Aug 2017 Status changed from active, no longer recruiting to completed.
- 11 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 28 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.